JP2022500483A5 - - Google Patents
Info
- Publication number
- JP2022500483A5 JP2022500483A5 JP2021516719A JP2021516719A JP2022500483A5 JP 2022500483 A5 JP2022500483 A5 JP 2022500483A5 JP 2021516719 A JP2021516719 A JP 2021516719A JP 2021516719 A JP2021516719 A JP 2021516719A JP 2022500483 A5 JP2022500483 A5 JP 2022500483A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- vomiting
- lys
- day
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024077833A JP2024105512A (ja) | 2018-09-24 | 2024-05-13 | Ｇｉｐ受容体アゴニストペプチド化合物及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862735510P | 2018-09-24 | 2018-09-24 | |
| US62/735,510 | 2018-09-24 | ||
| PCT/JP2019/038827 WO2020067575A1 (en) | 2018-09-24 | 2019-09-24 | Gip receptor agonist peptide compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024077833A Division JP2024105512A (ja) | 2018-09-24 | 2024-05-13 | Ｇｉｐ受容体アゴニストペプチド化合物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500483A JP2022500483A (ja) | 2022-01-04 |
| JP2022500483A5 true JP2022500483A5 (enExample) | 2022-10-03 |
| JP7511548B2 JP7511548B2 (ja) | 2024-07-05 |
Family
ID=68344956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516719A Active JP7511548B2 (ja) | 2018-09-24 | 2019-09-24 | Ｇｉｐ受容体アゴニストペプチド化合物及びその使用 |
| JP2024077833A Pending JP2024105512A (ja) | 2018-09-24 | 2024-05-13 | Ｇｉｐ受容体アゴニストペプチド化合物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024077833A Pending JP2024105512A (ja) | 2018-09-24 | 2024-05-13 | Ｇｉｐ受容体アゴニストペプチド化合物及びその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220016215A1 (enExample) |
| EP (1) | EP3856339A1 (enExample) |
| JP (2) | JP7511548B2 (enExample) |
| WO (1) | WO2020067575A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119471A1 (es) | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| IL296592A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
| CN118754965A (zh) | 2020-05-29 | 2024-10-11 | 北京拓界生物医药科技有限公司 | Glp-1和gip受体双重激动剂化合物及其应用 |
| CN116635055A (zh) * | 2020-10-16 | 2023-08-22 | 韩美药品株式会社 | 包括gip衍生物或其长效缀合物的用于预防或治疗狼疮相关疾病的药物组合物 |
| CN116583533A (zh) | 2020-10-16 | 2023-08-11 | 韩美药品株式会社 | Gip衍生物、其长效缀合物和包括其的药物组合物 |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CN117866050A (zh) * | 2021-05-28 | 2024-04-12 | 广东众生睿创生物科技有限公司 | 多肽的制备及其应用 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7886963B2 (ja) * | 2022-04-07 | 2026-07-08 | 広東衆生睿創生物科技有限公司 | 糖尿病、肥満症およびその関連疾患を治療および／または予防するための医薬品の調製における、ポリペプチドの医薬的使用 |
| CN119894921A (zh) * | 2022-09-15 | 2025-04-25 | 伊莱利利公司 | Gip和glp-1双重激动剂化合物 |
| CN120349392A (zh) * | 2023-11-06 | 2025-07-22 | 成都奥达生物科技有限公司 | 一种gip激动剂化合物 |
| WO2025154020A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
| WO2025154021A1 (en) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Improved gip receptor agonist peptide compounds and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| US7057012B1 (en) * | 1998-12-31 | 2006-06-06 | The General Hospital Corporation | PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| BR0315815A (pt) | 2002-11-01 | 2005-09-13 | Takeda Pharmaceutical | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| WO2005058823A1 (ja) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| CA2597649A1 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
| US20090054435A1 (en) * | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| JP4094660B1 (ja) | 2005-08-10 | 2008-06-04 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| AU2007265966B2 (en) | 2006-06-27 | 2012-05-17 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
| US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| CN101573357B (zh) | 2006-10-19 | 2013-01-23 | 武田药品工业株式会社 | 吲哚化合物 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008215490A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of PPAR-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| ES2558842T3 (es) | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| KR20130133103A (ko) * | 2008-08-07 | 2013-12-05 | 입센 파마 에스.에이.에스 | Ｎ-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(ｇｉｐ)의 유사체 |
| US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
| KR102002783B1 (ko) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
| DK3004155T3 (da) * | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | Peptidforbindelse |
| EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
| AR103242A1 (es) | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| EP3467106B1 (en) * | 2016-05-24 | 2025-07-09 | Takeda Pharmaceutical Company Limited | Peptide compound |
| JOP20190211A1 (ar) * | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| AR119471A1 (es) * | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| IL296592A (en) * | 2020-03-25 | 2022-11-01 | Takeda Pharmaceuticals Co | Qd dosing of gip receptor agonist peptide compounds and uses thereof |
-
2019
- 2019-09-24 US US17/279,228 patent/US20220016215A1/en active Pending
- 2019-09-24 EP EP19794712.0A patent/EP3856339A1/en active Pending
- 2019-09-24 WO PCT/JP2019/038827 patent/WO2020067575A1/en not_active Ceased
- 2019-09-24 JP JP2021516719A patent/JP7511548B2/ja active Active
-
2024
- 2024-05-13 JP JP2024077833A patent/JP2024105512A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023012547A5 (enExample) | ||
| US12054501B2 (en) | Compositions and methods for inhibiting arginase activity | |
| US11684674B2 (en) | Oral formulations of kappa opioid receptor agonists | |
| JP2023519446A5 (enExample) | ||
| IL269581B1 (en) | GIP receptor activating peptide | |
| Donnelly et al. | Morphine in cancer pain management: a practical guide | |
| CN1080118C (zh) | 冻干的奥丹亚龙制剂 | |
| JP2023524603A5 (enExample) | ||
| JP2022537551A5 (enExample) | ||
| JP6342960B2 (ja) | 化学療法誘導嘔吐を治療するためのパロノセトロン | |
| RU2020109881A (ru) | Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита | |
| US20150258052A1 (en) | Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue | |
| WO2018082814A1 (en) | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis | |
| JPH10508866A (ja) | オンダンセトロンを含有する経口組成物 | |
| JP2002504516A (ja) | アンギオテンシンｉｉ型２リセプタ作用薬を含む医薬製剤およびその使用 | |
| TW201032817A (en) | Compounds | |
| US12503490B2 (en) | Method of treating Gram-negative bacterial infection with isolated darobactin compounds | |
| JP2021513552A5 (enExample) | ||
| TW200927146A (en) | Antibacterial aminoglycoside analogs | |
| CN101426500A (zh) | 治疗糖尿病和肥胖症的二肽基肽酶iv抑制剂和cb1受体拮抗剂的药物组合物 | |
| CN116113406B (zh) | Gas41抑制剂及其使用方法 | |
| JPWO2020250915A5 (enExample) | ||
| CN118946371A (zh) | 靶向psma的放射性药物和检查点抑制剂的组合疗法 | |
| US9573970B2 (en) | 4-{4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1H-pyrazol-3-yl beta-D glucopyranoside acetate | |
| CN111989092A (zh) | Bet抑制剂和蛋白酶体抑制剂的联合治疗 |